At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
TDVbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years
In Brief
A Phase 2 clinical trial evaluating TDV for Healthy Volunteers. Completed, enrolled 200 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the cellular immune responses following 2 doses given 3 months apart of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesPanama, Philippines
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartApr 2017
Primary CompletionOct 2017
Study CompletionDec 2020
TodayJul 2026
First PostedOct 28, 2016
Enrollment StartApr 3, 2017
Primary CompletionOct 16, 2017
Study CompletionDec 14, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.7 years ago
Interventions
TDVbiological
TDV SC injection.